文献速递艾滋病与性传播感染

替诺福韦艾拉酚胺与替诺福韦二吡呋酯的精液浓度、病毒抑制及精液质量比较

Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
PubMed 文献 · Clin Infect Dis · 2019-01-01

这项前瞻性开放标签单臂研究纳入14名病毒学抑制的HIV-1感染男性,从艾维雷韦/考比司他/恩曲他滨/替诺福韦二吡呋酯(E/C/F/TDF)转换为E/C/F/替诺福韦艾拉酚胺(TAF)。转换12周后,TAF组精浆中替诺福韦(TFV)谷浓度(C24h)比血将高11.9倍,但显著低于TDF组精浆TFV C24h,仍为50%抑制浓度(IC50,11.5 ng/mL)的9.6倍。TAF组精液单核细胞(SMC)中TFV-二磷酸(TFV-dp)浓度仅为外周血单核细胞(PBMC)的6%,SMC:PBMC比值显著低于TDF组,但SMC中TFV-dp C24h与TDF组相当。所有患者在基线和转换后12周血将和精浆HIV-1 RNA均<40拷贝/mL,精液质量无显著差异。

要点

  • TAF组精浆TFV C24h为血将的11.9倍,仍高于IC50(11.5 ng/mL)9.6倍。
  • TAF组SMC中TFV-dp仅为PBMC的6%,SMC:PBMC比值显著低于TDF。
  • 转换TAF后12周,血将和精浆HIV-1 RNA均维持<40拷贝/mL,精液质量无显著变化。

核心结论

  • TAF与TDF在精液细胞外和细胞内的TFV分布不同,但联合E/C/F均能维持精液HIV-1 RNA抑制。
  • 男性生殖道分布差异未伴随精液质量的差异。

研究设计与样本

  • 前瞻性、开放标签、单臂研究,纳入14名病毒学抑制的HIV-1感染男性,从E/C/F/TDF转换为E/C/F/TAF。
  • 在基线(转换前)和转换后12周测量血将和精浆HIV-1 RNA、TFV浓度、PBMC和SMC中TFV-dp浓度(C24h),并评估精液质量。

主要发现

  • TAF组精浆TFV C24h为血将的11.9倍,显著低于TDF组精浆TFV C24h,但为IC50(11.5 ng/mL)的9.6倍。
  • TAF组SMC中TFV-dp中位浓度为PBMC的6%,SMC:PBMC比值显著低于TDF组。
  • TAF组SMC中TFV-dp C24h与TDF组相当。
  • 基线和转换后12周,所有患者血将和精浆HIV-1 RNA均<40拷贝/mL。
  • TAF与TDF组间精液质量无显著差异。

关键数值与推荐

  • TAF组精浆TFV C24h为血将的11.9倍。
  • TAF组精浆TFV C24h为IC50(11.5 ng/mL)的9.6倍。
  • TAF组SMC中TFV-dp中位浓度为PBMC的6%。
  • 血将和精浆HIV-1 RNA抑制标准为<40拷贝/mL。

临床怎么用

  • 对于病毒学抑制的HIV-1感染者,转换为含TAF方案仍可维持精液病毒抑制。
  • TAF与TDF在男性生殖道的药物分布存在差异,但精液质量无显著变化。

局限性

  • 研究为单臂、开放标签、样本量小(14人),缺乏随机对照。
  • 随访时间较短(转换后12周)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study assessed the penetration and efficacy of tenofovir alafenamide (TAF) in the male genital tract (MGT) and the semen quality of individuals infected with human immunodeficiency virus (HIV)-1 who were treated with a TAF-containing regimen. METHODS: This was a prospective, open-label, single-arm study of 14 virologically-suppressed, HIV-1-infected men on stable antiretroviral therapy with elvitegravir, cobicistat, emtricitabine (E/C/F) and tenofovir disoproxil fumarate (TDF) who switched to E/C/F and TAF. At baseline (pre-switch) and at 12 weeks post-switch, we measured HIV-1 RNA in seminal plasma (SP) and blood plasma (BP), tenofovir (TFV) in SP and BP, and TFV-diphosphate (dp) in peripheral blood mononuclear cells (PBMCs) and seminal mononuclear cells (SMCs) at the end of the dosing interval (C24h). Semen quality was assessed before switching and after 12 weeks on TAF. RESULTS: With TAF, TFV C24 was 11.9-fold higher in SP than in BP. This concentration was significantly lower than TFV C24 in SP with TDF, but 9.6-fold higher than the 50% inhibitory concentration (IC50) (11.5 ng/mL). By contrast, the median TFV-dp concentration achieved with TAF in SMCs was 6% that of TFV-dp in PBMCs. The TFV-dp SMC:PBMC ratio was also significantly lower with TAF. Nonetheless, TFV-dp C24 in SMC was comparable with TAF and TDF. All the patients had HIV-1 RNA <40 copies/mL in BP and SP at baseline and at 12 weeks post-switch. No significant differences were observed in semen quality between TAF and TDF. CONCLUSIONS: Extracellular and intracellular seminal TFV distribution differs between TAF and TDF. Nevertheless, both formulations, combined with elvitegravir/cobicistat/emtricitabine, maintained HIV-1 RNA suppression in semen. Differences in MGT distribution were not associated with differences in semen quality. CLINICAL TRIALS REGISTRATION: EudraCT: 2016-001371-69.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Imaz A, Niubó J, Cottrell ML, et al. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40). Clin Infect Dis. 2019. PMID: 30561517. doi:10.1093/cid/ciy1074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。